The newly appointed Supervisory Board of Merck has elected at its inaugural meeting Wolfgang Büchele as the Chairman of this corporate governance body. Before that, the Annual General Meeting had elected the eight shareholder representatives.
The eight employee representative members of the Supervisory Board had already been elected in April. The term of office of the previous Supervisory Board members expired upon conclusion of the Annual General Meeting. The new term of office runs until the conclusion of the Annual General Meeting that will resolve on the approval of the actions of the Executive Board for fiscal 2018.
At today's Annual General Meeting, the shareholders also approved the increase of €0.20 in the dividend to €1.90, which corresponds to a total dividend payment of approximately €413 million and a payout ratio of around 31%. Shareholders also voted in favour of the proposed 2:1 share split.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze